In the News

GenomeWeb: Epic Sciences Collaborators Share Data at AACR on Single Cancer Cell Analysis, CTC Biomarker Detection

Epic’s San Diego Lab Gains CLIA Certification

Lung Cancer News Today: Epic Sciences to Present CTC-cfDNA Method for Lung Cancer Analysis

Epic’s no cell left behind™ technology allows for a full assessment of non-small cell lung cancer (NSCLC) biomarkers from a single tube of blood, inclusive of EGFR, KRAS, ALK, MET, RET and ROS1.

Cancer Discovery: Tracking CTCs May Improve Cancer Treatment

The Scientist: Capturing Cancer Cells on the Move

Discover Magazine: Personalized Cancer Treament, From Just a Blood Sample

Xconomy: Epic Sciences Compiling Data on Ultra-Sensitive Cancer Diagnostic

New assay could help predict onset of MI

U-T San Diego: Scripps invents way to spot spread of cancer

MedCity News: Cancer diagnostics firm that can enable personalized medicine raises $13M in series B financing

Xconomist of the Week: Peter Kuhn on Detecting Circulating Tumor Cells

Prostate Cancer Foundation: CTC technology detects presence of cancer and serves as a less invasive diagnostic tool

Epic and Scripps publish five manuscripts in Physical Biology

Clinical Oncology: Circulating Tumor Cells: The Ultimate Assay?